Clinical Guidelines for Olfactory Dysfunction Follow-Up

Abstract

Olfactory dysfunction, encompassing anosmia and hyposmia, poses significant implications for patient safety, nutrition, and quality of life. This review provides an evidence-based synthesis of current clinical guidelines for the follow-up and management of olfactory dysfunction. It integrates recent advances in diagnostic modalities, highlights the disease burden, elucidates mechanisms of olfactory impairment, discusses risk factors and clinical features, and presents updated treatment strategies and recommendations. Special emphasis is placed on practical clinical approaches, patient stratification, and emerging therapeutic modalities, enabling healthcare professionals to deliver guideline-concordant, patient-centered care.

Introduction

Olfactory dysfunction refers to partial or complete loss of smell sensation and can be a manifestation of multiple underlying etiologies, ranging from sinonasal disease and viral infections to neurodegenerative disorders. The COVID-19 pandemic further amplified the clinical focus on olfaction due to the high prevalence of acute anosmia among affected individuals. Appreciating the complexities of olfactory impairment is essential for early identification, targeted management, and effective follow-up. Recent clinical guidelines underscore the need for a structured approach, incorporating robust diagnostic assessment, ongoing monitoring, and tailored interventions based on etiology and patient profile.

Epidemiology / Disease Burden

Olfactory dysfunction affects approximately 3–20% of the general population, with prevalence rates escalating in the elderly. Epidemiological studies underscore notable underdiagnosis, particularly among primary care cohorts, despite its profound impact on safety (e.g., inability to detect smoke or spoiled food), nutrition, and psychosocial health. The COVID-19 pandemic led to a surge in cases, with some studies reporting olfactory loss in up to 60% of infected individuals; while many recover, a significant subset experiences persistent dysfunction. The burden is further compounded by associations with depression, reduced appetite, and impaired daily functioning, underscoring the necessity for systematic follow-up and multidisciplinary care.

Pathophysiology

Olfactory dysfunction arises from a spectrum of mechanisms. Conductive loss results from obstruction (e.g., nasal polyps), impeding odorant access to the olfactory epithelium. Sensorineural loss stems from direct injury to olfactory receptor neurons (as in post-viral or traumatic cases) or neurodegeneration affecting olfactory pathways (e.g., Parkinson's, Alzheimer's). COVID-19-related anosmia appears to involve both direct viral effects on sustentacular cells and inflammatory-mediated neuronal injury. Understanding these mechanisms enables clinicians to tailor investigative and therapeutic strategies and informs prognosis estimation during follow-up.

Risk Factors

Risk factors for olfactory dysfunction span patient demographics and underlying comorbidities. Advanced age is a prominent risk, with age-related decline in olfactory neuron regeneration and cumulative environmental insults. Other risk factors include chronic rhinosinusitis, allergic rhinitis, upper respiratory infections, head trauma, neurodegenerative diseases, tobacco use, and certain medications (e.g., intranasal zinc, some antibiotics). Genetic predisposition and prior craniofacial surgery may also contribute. Recognizing these risks is critical for early identification and risk stratification in clinical practice.

Clinical Features

Patients may present with quantitative (anosmia, hyposmia) or qualitative (parosmia, phantosmia) olfactory disturbances. Associated symptoms may include nasal congestion, rhinorrhea, or headache (in sinonasal disease), memory or cognitive decline (in neurodegenerative conditions), or recent viral illness. Careful history-taking should explore onset, duration, progression, associated symptoms, medication use, exposure history, and impact on daily life, with particular attention to safety concerns and nutritional status.

Diagnosis

Diagnosis begins with a structured clinical assessment, incorporating detailed history and focused nasal and neurological examination. Objective olfactory testing is essential for quantification; validated psychophysical tests include the University of Pennsylvania Smell Identification Test (UPSIT), Sniffin Sticks, and the Connecticut Chemosensory Clinical Research Center (CCCRC) test. Nasal endoscopy is indicated to evaluate for mechanical obstruction or sinonasal disease. Imaging (CT or MRI) is reserved for patients with atypical features, persistent unexplained loss, or suspicion of intracranial pathology. Laboratory testing may be warranted for suspected systemic or neurodegenerative etiologies. Reassessment at defined intervals is crucial to monitor recovery or progression.

Treatment & Management

Management is etiology-driven. For conductive loss, medical therapy (e.g., topical corticosteroids, saline irrigations) and surgical intervention (e.g., polypectomy) may be effective. In post-viral or idiopathic cases, olfactory training has emerged as a cornerstone, leveraging neuroplasticity through repeated odorant exposure. Adjunctive therapies may include short courses of systemic steroids (with careful risk-benefit assessment) and, in select cases, vitamin A or alpha-lipoic acid. Management of underlying comorbidities (e.g., allergic rhinitis, chronic sinusitis) is essential. Multidisciplinary collaboration, including referral to otolaryngology and neurology, is recommended for refractory or complex cases. Patient education regarding safety (e.g., smoke detectors), nutrition, and psychological support is integral to care.

Recent Advances / Emerging Therapies

Recent advances include novel olfactory training paradigms with increased odorant diversity and intensity, as well as digital platforms enhancing adherence. Topical therapeutics targeting neuroinflammation and neuroregeneration are under investigation. Stem cell and gene therapies represent promising experimental frontiers. For post-COVID-19 anosmia, randomized trials are exploring the efficacy of intranasal corticosteroids, platelet-rich plasma, and neurotrophic factor analogs. Improved imaging modalities and biomarker discovery are enhancing diagnostic precision, facilitating personalized follow-up regimens.

Guideline Recommendations

Consensus guidelines from major otolaryngology and neurology societies advocate a structured diagnostic and management algorithm. Key recommendations include: (1) thorough history and exam for all patients; (2) objective olfactory testing for diagnosis and follow-up; (3) nasal endoscopy for suspected sinonasal pathology; (4) imaging when indicated; (5) olfactory training as first-line therapy for post-viral/idiopathic loss; (6) tailored pharmacotherapy based on etiology; (7) scheduled follow-up for recovery assessment; (8) early referral for refractory or atypical cases; and (9) patient counseling on safety and nutrition. Documentation of baseline and interval olfactory function is emphasized for optimal longitudinal care.

Conclusion

Olfactory dysfunction represents a prevalent yet often underappreciated clinical entity with far-reaching implications. Recent evidence and evolving guidelines highlight the necessity for structured assessment, risk stratification, and individualized follow-up. Integration of objective testing, mechanism-based therapies, patient education, and multidisciplinary collaboration is essential for optimizing outcomes. Ongoing research into emerging therapies and biomarkers will likely refine future management paradigms, underscoring the importance of continued clinical vigilance and evidence-based practice in the follow-up of olfactory dysfunction.